Larimar Therapeutics Inc Financials
This page shows Larimar Therapeutics Inc (LRMR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A pre-revenue model is funding a rapidly larger R&D burn, and financing has not fully rebuilt the cash cushion.
In the latest year, R&D more than doubled to$154.2M while SG&A stayed near$18.3M , and operating cash burn deepened in parallel with that mix. The operating model therefore became more research-intensive rather than simply more expensive across the company.
Headline cash ended at
The balance sheet remains equity-financed because there is no reported long-term debt, so fresh capital has come mainly from issuing shares rather than borrowing, which avoids interest costs but shifts funding onto dilution. That tradeoff is visible in the jump from 63.8M to 83.1M shares outstanding, which added liquidity without adding interest burden.
Financial Health Signals
Larimar Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Larimar Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Larimar Therapeutics Inc reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Larimar Therapeutics Inc's EBITDA was -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 90.1% from the prior year.
Larimar Therapeutics Inc reported -$165.7M in net income in fiscal year 2025. This represents a decrease of 105.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Larimar Therapeutics Inc recorded an outflow of $113.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 59.0% from the prior year.
Larimar Therapeutics Inc held $85.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Larimar Therapeutics Inc's ROE was -212.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 165.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Larimar Therapeutics Inc invested $154.2M in research and development in fiscal year 2025. This represents an increase of 110.5% from the prior year.
Larimar Therapeutics Inc invested $91K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 82.3% from the prior year.
Not reported for fiscal year 2025.
LRMR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D Expenses | $154.2M+110.5% | $73.3M+164.8% | $27.7M+14.1% | $24.3M-36.8% | $38.4M+22.3% | $31.4M+51.1% | $20.8M-56.6% | $47.9M+17.4% | $40.8M+2.3% | $39.9M-26.9% | $54.6M+99.4% | $27.4M+186.5% | $9.6M-17.2% | $11.5M |
| SG&A Expenses | $18.3M+3.8% | $17.6M+25.0% | $14.1M+14.8% | $12.3M+1.7% | $12.1M+5.9% | $11.4M+370.2% | $2.4M-81.6% | $13.2M+8.5% | $12.2M-33.5% | $18.3M-4.7% | $19.2M+135.8% | $8.1M+93.0% | $4.2M+87.8% | $2.2M |
| Operating Income | -$172.5M-89.8% | -$90.9M-117.7% | -$41.8M-14.3% | -$36.5M+27.6% | -$50.5M-17.9% | -$42.8M-84.4% | -$23.2M+62.0% | -$61.1M-15.3% | -$53.0M+9.0% | -$58.2M+21.1% | -$73.8M-107.7% | -$35.5M-157.9% | -$13.8M+0.1% | -$13.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $1.8M-7.0% | $1.9M+1050.3% | $165K-68.8% | $529K-34.4% | $806K-7.4% | $870K | N/A | $97K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$165.7M-105.5% | -$80.6M-118.1% | -$36.9M-4.5% | -$35.4M+30.2% | -$50.6M-19.2% | -$42.5M-83.7% | -$23.1M+62.3% | -$61.4M-18.0% | -$52.0M+10.1% | -$57.9M+22.1% | -$74.3M-103.6% | -$36.5M-160.1% | -$14.0M-1.1% | -$13.9M |
| EPS (Diluted) | N/A | -$1.32-57.1% | -$0.84 | -$1.37 | -$2.95+17.4% | -$3.57 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
LRMR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $145.8M-27.2% | $200.2M+108.7% | $95.9M-24.1% | $126.4M+60.7% | $78.7M-24.9% | $104.7M+1912.8% | $5.2M-95.7% | $121.8M+15.4% | $105.5M-19.8% | $131.6M-30.4% | $189.1M+60.9% | $117.5M+208.1% | $38.1M | N/A |
| Current Assets | $142.0M-27.3% | $195.3M+116.6% | $90.2M-25.3% | $120.7M+67.2% | $72.2M-26.3% | $98.0M+1962.1% | $4.8M-96.1% | $121.3M+15.6% | $104.9M-19.8% | $130.9M-30.4% | $188.1M+60.5% | $117.2M+213.7% | $37.4M | N/A |
| Cash & Equivalents | $85.4M+157.1% | $33.2M+24.2% | $26.7M-0.3% | $26.8M-61.7% | $70.1M+2.9% | $68.1M+6654.0% | $1.0M-98.0% | $49.3M+21.0% | $40.8M+26.0% | $32.4M-9.1% | $35.6M-38.7% | $58.1M+63.6% | $35.5M+257.5% | $9.9M |
| Total Liabilities | $67.8M+138.5% | $28.4M+99.9% | $14.2M-8.3% | $15.5M+8.8% | $14.3M-4.9% | $15.0M+154.4% | $5.9M-95.0% | $118.8M+335.5% | $27.3M+175.9% | $9.9M-50.5% | $20.0M+52.9% | $13.1M-87.7% | $106.7M | N/A |
| Current Liabilities | $64.8M+166.0% | $24.4M+156.2% | $9.5M-11.2% | $10.7M+21.0% | $8.8M-1.6% | $9.0M+52.5% | $5.9M-55.7% | $13.3M+82.4% | $7.3M-26.3% | $9.9M-40.2% | $16.5M+139.7% | $6.9M+136.7% | $2.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $20.0M0.0% | $20.0M+528.3% | $3.2M | N/A | N/A | N/A | N/A |
| Total Equity | $78.1M-54.6% | $171.8M+110.2% | $81.7M-26.3% | $110.9M+72.2% | $64.4M-28.2% | $89.7M+13023.9% | -$694K-123.8% | $2.9M-96.3% | $78.2M-35.7% | $121.7M-28.0% | $169.1M+61.9% | $104.4M+252.3% | -$68.6M-25.3% | -$54.7M |
| Retained Earnings | -$434.8M-61.6% | -$269.2M-42.7% | -$188.6M-24.4% | -$151.6M-30.4% | -$116.3M-77.2% | -$65.6M-183.7% | -$23.1M+93.4% | -$350.9M-21.2% | -$289.6M-21.9% | -$237.5M-32.2% | -$179.7M-70.5% | -$105.4M-52.9% | -$68.9M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
LRMR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$113.2M-60.0% | -$70.8M-111.5% | -$33.5M-21.4% | -$27.6M+34.5% | -$42.1M+0.2% | -$42.2M-85.9% | -$22.7M+55.9% | -$51.5M-17.6% | -$43.8M+15.8% | -$52.0M+12.7% | -$59.6M-110.9% | -$28.2M-88.2% | -$15.0M-10.4% | -$13.6M |
| Capital Expenditures | $91K-82.3% | $515K+214.0% | $164K+64.0% | $100K-70.0% | $333K+437.1% | $62K-25.3% | $83K-23.1% | $108K+96.4% | $55K-91.7% | $660K+10.9% | $595K+925.9% | $58K+241.2% | $17K+750.0% | $2K |
| Free Cash Flow | -$113.3M-59.0% | -$71.3M-112.0% | -$33.6M-21.5% | -$27.7M+34.8% | -$42.4M-0.4% | -$42.3M-85.5% | -$22.8M+55.8% | -$51.6M-17.7% | -$43.8M+16.7% | -$52.6M+12.5% | -$60.1M-112.5% | -$28.3M-88.4% | -$15.0M-10.5% | -$13.6M |
| Investing Cash Flow | $100.3M+217.5% | -$85.4M-356.0% | $33.4M+136.7% | -$91.0M-476.3% | $24.2M+41.4% | $17.1M+20690.4% | -$83K+98.8% | -$6.9M-119.3% | $35.6M-30.7% | $51.4M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $65.1M-59.8% | $161.9M+539510.0% | $30K-100.0% | $75.3M+278.5% | $19.9M-78.8% | $93.6M+382.5% | $19.4M-71.0% | $66.9M+304.0% | $16.6M+710.0% | -$2.7M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
LRMR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -212.2%-165.3pp | -46.9%-1.7pp | -45.2%-13.3pp | -31.9%+46.7pp | -78.6%-31.3pp | -47.4% | N/A | -2106.0%-2039.5pp | -66.5%-19.0pp | -47.5%-3.6pp | -43.9%-9.0pp | -34.9% | N/A | N/A |
| Return on Assets | -113.6%-73.3pp | -40.3%-1.8pp | -38.5%-10.5pp | -28.0%+36.4pp | -64.4%-23.8pp | -40.6%+404.2pp | -444.8%-394.4pp | -50.4%-1.1pp | -49.3%-5.3pp | -44.0%-4.7pp | -39.3%-8.2pp | -31.0%+5.7pp | -36.8% | N/A |
| Current Ratio | 2.19-5.8x | 8.02-1.5x | 9.49-1.8x | 11.28+3.1x | 8.16-2.7x | 10.89+10.1x | 0.81-8.3x | 9.12-5.3x | 14.39+1.2x | 13.23+1.9x | 11.37-5.6x | 16.98+4.2x | 12.82 | N/A |
| Debt-to-Equity | 0.87+0.7x | 0.170.0x | 0.170.0x | 0.14-0.1x | 0.22+0.1x | 0.17 | N/A | 6.86+6.6x | 0.26+0.2x | 0.03-0.1x | 0.120.0x | 0.13 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Larimar Therapeutics Inc Ranks
Frequently Asked Questions
Is Larimar Therapeutics Inc profitable?
No, Larimar Therapeutics Inc (LRMR) reported a net income of -$165.7M in fiscal year 2025.
What is Larimar Therapeutics Inc's EBITDA?
Larimar Therapeutics Inc (LRMR) had EBITDA of -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Larimar Therapeutics Inc's return on equity (ROE)?
Larimar Therapeutics Inc (LRMR) has a return on equity of -212.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Larimar Therapeutics Inc's free cash flow?
Larimar Therapeutics Inc (LRMR) recorded an outflow of $113.3M in free cash flow during fiscal year 2025. This represents a -59.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Larimar Therapeutics Inc's operating cash flow?
Larimar Therapeutics Inc (LRMR) recorded an outflow of $113.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Larimar Therapeutics Inc's total assets?
Larimar Therapeutics Inc (LRMR) had $145.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Larimar Therapeutics Inc's capital expenditures?
Larimar Therapeutics Inc (LRMR) invested $91K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Larimar Therapeutics Inc spend on research and development?
Larimar Therapeutics Inc (LRMR) invested $154.2M in research and development during fiscal year 2025.
What is Larimar Therapeutics Inc's current ratio?
Larimar Therapeutics Inc (LRMR) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.
What is Larimar Therapeutics Inc's debt-to-equity ratio?
Larimar Therapeutics Inc (LRMR) had a debt-to-equity ratio of 0.87 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Larimar Therapeutics Inc's return on assets (ROA)?
Larimar Therapeutics Inc (LRMR) had a return on assets of -113.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Larimar Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Larimar Therapeutics Inc (LRMR) had $85.4M in cash against an annual operating cash burn of $113.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Larimar Therapeutics Inc's Piotroski F-Score?
Larimar Therapeutics Inc (LRMR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Larimar Therapeutics Inc's earnings high quality?
Larimar Therapeutics Inc (LRMR) reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.